Table 4 Incidence and severity of hypersensitivity adverse events, all causality
| Â | Pegaptanib 0.3 mg | |||||||
|---|---|---|---|---|---|---|---|---|
Number of Subjects | With Diabetes | Without Diabetes | ||||||
|  | (N = 165) | (N = 1421) | ||||||
Preferred Term 1 | n | (%) | Severe | LT | n | (%) | Severe | LT |
Blepharitis, allergic | 0 | 0 | 0 | 0 | 1 | (0.1) | 0 | 0 |
Dermatitis, allergic | 0 | 0 | 0 | 0 | 1 | (0.1) | 0 | 0 |
Dermatitis, contact | 0 | 0 | 0 | 0 | 7 | (0.5) | 0 | 0 |
Drug hypersensitivity | 0 | 0 | 0 | 0 | 6 | (0.4) | 0 | 0 |
Erythema | 0 | 0 | 0 | 0 | 2 | (0.1) | 0 | 0 |
Hypersensitivity | 0 | 0 | 0 | 0 | 2 | (0.1) | 0 | 0 |
Hypersensitivity NOS | 0 | 0 | 0 | 0 | 5 | (0.4) | 0 | 0 |
Rash | 0 | 0 | 0 | 0 | 2 | (0.1) | 0 | 0 |
Rash NOS | 2 | (1.2) | 0 | 0 | 12 | (0.8) | 0 | 0 |
Toxic skin eruption | 0 | 0 | 0 | 0 | 1 | (0.1) | 0 | 0 |
Urticaria | 0 | 0 | 0 | 0 | 1 | (0.1) | 0 | 0 |